Overview

* Corbus Pharmaceuticals ( CRBP ) Q3 net loss widens to $23.3 mln, driven by clinical development costs

* Company completed $75 mln public offering, extending cash runway into 2028

* CRB-701 clinical data shows promising ORR in HNSCC, cervical, and bladder cancers

Outlook

* Company plans to meet FDA in Q1 2026 for CRB-701 data review

* Corbus expects to start CRB-701 Phase 2/3 study by mid-2026

* Company to complete CRB-913 SAD/MAD study by end of 2025

Result Drivers

* R&D - Operating expenses increased by $8.9 million to approximately $24.4 million for the three months ended September 30, 2025, compared to approximately $15.5 million for the three months ended September 30, 2024.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$23.34

Income mln

Q3 Basic -$1.90

EPS

Q3 $24.42

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Corbus Pharmaceuticals Holdings Inc ( CRBP ) is $40.00, about 73.9% above its November 11 closing price of $10.42

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)